These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 30777651)

  • 21. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance.
    Samotus O; Lee J; Jog M
    J Neurol; 2018 Jun; 265(6):1269-1278. PubMed ID: 29557988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis: a pilot study.
    Boon AJ; Smith J; Dahm DL; Sorenson EJ; Larson DR; Fitz-Gibbon PD; Dykstra DD; Singh JA
    PM R; 2010 Apr; 2(4):268-76. PubMed ID: 20430328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
    Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
    Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pilot randomized controlled trial of brief cognitive-behavioral therapy for anxiety in patients with terminal cancer.
    Greer JA; Traeger L; Bemis H; Solis J; Hendriksen ES; Park ER; Pirl WF; Temel JS; Prigerson HG; Safren SA
    Oncologist; 2012; 17(10):1337-45. PubMed ID: 22688670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
    Poewe W; Burbaud P; Castelnovo G; Jost WH; Ceballos-Baumann AO; Banach M; Potulska-Chromik A; Ferreira JJ; Bihari K; Ehler E; Bares M; Dzyak LA; Belova AN; Pham E; Liu WJ; Picaut P
    Mov Disord; 2016 Nov; 31(11):1649-1657. PubMed ID: 27653448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia.
    Chughtai B; Dunphy C; Lee R; Lee D; Sheth S; Marks L; Kaplan SA; Te AE
    Can J Urol; 2014 Apr; 21(2):7217-21. PubMed ID: 24775575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients.
    Chen TY; Garza I; Dodick DW; Robertson CE
    Headache; 2018 Jul; 58(7):973-985. PubMed ID: 29762872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part I): muscle afferent block versus botulinum toxin-A in cervical and limb dystonias.
    Rosales RL; Santos MM; Ng AR; Teleg R; Dantes M; Lee LV; Fernandez HH
    Int J Neurosci; 2011; 121 Suppl 1():35-43. PubMed ID: 21244305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Facial asymmetry in patients with hemifacial spasm before and after botulinum toxin A treatment.
    Xiao L; Pan Y; Zhang X; Hu Y; Cai L; Nie Z; Pan L; Li B; He Y; Jin L
    Neurol Sci; 2016 Nov; 37(11):1807-1813. PubMed ID: 27431279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose botulinum toxin-a treatment of cervical dystonia - a double-blind, randomized pilot study.
    Laubis-Herrmann U; Fries K; Topka H
    Eur Neurol; 2002; 47(4):214-21. PubMed ID: 12037435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
    Pappert EJ; Germanson T;
    Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Botulinum neurotoxins for the treatment of focal dystonias: Review of rating tools used in clinical trials.
    Del Sorbo F; Albanese A
    Toxicon; 2015 Dec; 107(Pt A):89-97. PubMed ID: 26365917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.
    Marberger M; Chartier-Kastler E; Egerdie B; Lee KS; Grosse J; Bugarin D; Zhou J; Patel A; Haag-Molkenteller C
    Eur Urol; 2013 Mar; 63(3):496-503. PubMed ID: 23098762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Botulin A toxin: a highly effective drug in the treatment of focal dystonia].
    Timerbaeva SL; Ivanova-Smolenskaia IA; Markova ED; Poleshchuk VV; Karapetian MV; Rebrova OIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(5):32-5. PubMed ID: 10849964
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland.
    Durham RC; Chambers JA; Power KG; Sharp DM; Macdonald RR; Major KA; Dow MG; Gumley AI
    Health Technol Assess; 2005 Nov; 9(42):1-174. PubMed ID: 16266559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Use of botulinum toxin type A in neuro-ORL].
    Périé S; Lacau St Guily J
    Ann Readapt Med Phys; 2003 Jul; 46(6):375-9. PubMed ID: 12928145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Onabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled study.
    Ondo WG; Simmons JH; Shahid MH; Hashem V; Hunter C; Jankovic J
    Neurology; 2018 Feb; 90(7):e559-e564. PubMed ID: 29343468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
    Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
    Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.